• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Medical Devices

  • Print
  • Share
  • E-mail

Baxter Colleague Single and Triple Channel Volumetric Infusion Pumps

Class 1 Recall
Date Recall
January 23, 2009

Baxter Colleague Single and Triple Channel Volumetric Infusion Pumps

Model numbers: Mono 2M8151 and 2M8153, CX 2M8161 and 2M8163, and CXE 2M9161and 2M9163

These products were manufactured and distributed from February, 1997 through December, 2008.

Electronic infusion pumps deliver controlled amounts of medications or other fluids to patients through an intravenous (IV), intra-arterial (IA), epidural, and other acceptable routes of administration.
Recalling Firm:
Baxter Healthcare Corp.
Rt. 120 & Wilson Rd.
Round Lake, Illinois 60073
Reason for Recall:
The company identified software and battery usage failures that result in a delay in or interruption of infusion that may cause serious injury and/or death.
Public Contact:
Customers may call Baxter Healthcare Corp. at 1-800-843-7867
FDA District:
FDA Comment:

On January 23, 2009, the company sent a correction letter to all of its customers about failures that could lead to:

  • interruption of therapy
  • damaged battery messages
  • smoke and fire hazards
  • serious injury and/or death

The letter also:

  • advised institutions to have contingency plans to verify that back-up pumps are available
  • provided new steps for addressing an interruption of therapy with any failure code
  • provided instructions for addressing damaged battery messages
  • provided instructions for proper device cleaning

For more information about this recall, please see the company’s press release

Class 1 recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of the product will cause serious injury or death.

Health care professionals and consumers may report adverse reactions or quality problems experienced with the use of this product to the FDA's MedWatch Adverse Event Reporting program.  See the nearby link to MedWatch.